What is the ROE (Return on Equity) of Allovir this year?
The ROE of Allovir this year is -1.31 undefined.
Allovir ROE 2024
Allovir ROE
-1.31
Ticker
ALVR
ISIN
US0198181036
WKN
A2QAMR
In 2024, Allovir's return on equity (ROE) was -1.31, a 73.81% increase from the -0.75 ROE in the previous year.
Allovir Aktienanalyse
What does Allovir do?
Allovir Inc was founded in 2013 in Cambridge, Massachusetts and is a biopharmaceutical company specializing in the development and commercialization of cellular immunotherapies for viral infections. The idea behind the founding of Allovir was to develop a new generation of immunotherapies with the potential to treat virus-related diseases that were previously difficult to treat. Allovir's business model is based on the development and commercialization of cellular immunotherapies that rely on the patient's immune system to fight infections. The company focuses on two main areas: infectious diseases and cancer. Within these areas, Allovir focuses on the development of therapies for severe viral infections such as BK virus, cytomegalovirus (CMV), and adenovirus, as well as the development of therapies to combat cancer. Allovir's first product candidates are Viral Associated Diseases (VAD) cell therapies developed to treat infections caused by BK virus, CMV, and adenovirus. These therapies consist of virus-specific T cells that are extracted from the patient's blood, amplified and activated in the laboratory, and then reintroduced into the patient where they can directly attack and eliminate the virus. Another promising product that Allovir is currently developing is ALVR106, a cellular immunotherapy for the treatment of cancer. ALVR106 is a CAR-T cell therapy candidate that aims to target HER2-positive solid tumors. The active ingredient is based on certain T cells that have been modified to specifically recognize and attack tumor-specific antigens. Allovir has conducted several successful clinical trials in recent years and has achieved promising results. Significant progress was observed in a clinical trial for the treatment of BK virus infections in kidney transplant patients. Therapy with virus-specific T cells resulted in a significant reduction in viral load and improvement in kidney function. Allovir's therapy also showed promising results in a Phase 2 trial for the treatment of CMV in bone marrow transplant patients. Allovir has established a strong position in the field of cellular immunotherapies for viral infections in recent years. The company has built an impressive research and development platform and has an experienced team of researchers and developers. The clinical results of Allovir's products demonstrate a high potential for future developments, and the company is expected to continue to grow and innovate in the coming years. Allovir ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Allovir's Return on Equity (ROE)
Allovir's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Allovir's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Allovir's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Allovir’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Allovir stock
How has the Return on Equity (ROE) of Allovir developed compared to the previous year?
The ROE of Allovir has increased by 73.81% increased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Allovir?
A high ROE indicates that Allovir generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Allovir?
A low ROE can indicate that Allovir is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Allovir affect the company?
A change in ROE (Return on Equity) of Allovir can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Allovir?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Allovir?
Some factors that can influence Allovir's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Allovir pay?
Over the past 12 months, Allovir paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Allovir is expected to pay a dividend of 0 USD.
What is the dividend yield of Allovir?
The current dividend yield of Allovir is .
When does Allovir pay dividends?
Allovir pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Allovir?
Allovir paid dividends every year for the past 0 years.
What is the dividend of Allovir?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Allovir located?
Allovir is assigned to the 'Health' sector.
Wann musste ich die Aktien von Allovir kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Allovir from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.
When did Allovir pay the last dividend?
The last dividend was paid out on 11/18/2024.
What was the dividend of Allovir in the year 2023?
In the year 2023, Allovir distributed 0 USD as dividends.
In which currency does Allovir pay out the dividend?
The dividends of Allovir are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Allovir
Our stock analysis for Allovir Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Allovir Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
